Crossject | ALCJ FP | Supergenerics | France | Updates

This research has been commissioned and paid for by the company and does therefore not constitute an inducement caught by the prohibition under MiFID II

Crossject ^CR	Bloomberg ALCJ FP
Supergenerics / France	Web Site \| Investors Relation

Things are getting going...hopefully

Target

Upside 300%

Price (€) 1.84

Target Price (€) 7.35

Market Cap (€M) 75.9

Perf. 1W:	-4.27%
Perf. 1M:	-14.9%
Perf. 3M:	-14.9%
Perf Ytd:	-62.6%

10 day relative perf. to stoxx600:	-13.7%
20 day relative perf. to stoxx600:	-16.1%

EPS change18/08/2021 19:35

Download

Change in EPS	2021 : € 0.18 vs 0.18	-0.32%
	2022 : € 0.91 vs 0.91	-0.32%
We have only integrated the detailed numbers for FY20, which translate into a slightly lower EPS. However, the change is not meaningful given the still very low level of results of the company before its products reach the market.

20 Jun 22 Latest
A major breakthrough for Crossject

29 Mar 22 Earnings/sales releases
FY21: not very meaningful, as expected

17 Dec 21 Financing issue
New financing

24 Sep 21 Earnings/sales releases
H1 21: unsurprising (as usual)

31 Aug 21 EPS change
We have fine-tuned our numbers on the back of...

18 Aug 21 EPS change
We have only integrated the detailed numbers f...

18 Jun 21 Latest
Another good piece of news for the group

17 Jun 21 Latest
A licensing agreement for Zeneo Hydrocortison...

31 Mar 21 Earnings/sales releases
FY20 unsuprising; waiting for more

15 Dec 20 Financing issue
A double bond issue